MA54200A - Procédé industriel pour la préparation d'estétrol de pureté élevée - Google Patents
Procédé industriel pour la préparation d'estétrol de pureté élevéeInfo
- Publication number
- MA54200A MA54200A MA054200A MA54200A MA54200A MA 54200 A MA54200 A MA 54200A MA 054200 A MA054200 A MA 054200A MA 54200 A MA54200 A MA 54200A MA 54200 A MA54200 A MA 54200A
- Authority
- MA
- Morocco
- Prior art keywords
- estetrol
- preparation
- high purity
- industrial process
- industrial
- Prior art date
Links
- AJIPIJNNOJSSQC-NYLIRDPKSA-N estetrol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)[C@@H]4O)O)[C@@H]4[C@@H]3CCC2=C1 AJIPIJNNOJSSQC-NYLIRDPKSA-N 0.000 title 1
- 229950009589 estetrol Drugs 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
- C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J75/00—Processes for the preparation of steroids in general
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
- C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
- C07J1/0074—Esters
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Gynecology & Obstetrics (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Diabetes (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU1900315A HU231240B1 (hu) | 2019-09-03 | 2019-09-03 | Ipari eljárás nagytisztaságú ösztetrol hatóanyag előállítására |
| PCT/IB2020/058148 WO2021044302A1 (fr) | 2019-09-03 | 2020-09-02 | Procédé industriel pour la préparation d'estétrol de pureté élevée |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA54200A true MA54200A (fr) | 2022-04-27 |
| MA54200B1 MA54200B1 (fr) | 2023-02-28 |
Family
ID=89992977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA54200A MA54200B1 (fr) | 2019-09-03 | 2020-09-02 | Procédé industriel pour la préparation d'estétrol de pureté élevée |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US11633406B2 (fr) |
| EP (1) | EP3877395B1 (fr) |
| JP (1) | JP7265087B2 (fr) |
| KR (1) | KR20220071206A (fr) |
| CN (1) | CN114302889B (fr) |
| AU (1) | AU2020343497B2 (fr) |
| CA (1) | CA3147815C (fr) |
| CL (1) | CL2022000492A1 (fr) |
| CO (1) | CO2022003769A2 (fr) |
| CU (1) | CU24692B1 (fr) |
| DK (1) | DK3877395T3 (fr) |
| EC (1) | ECSP22022403A (fr) |
| ES (1) | ES2855923T3 (fr) |
| FI (1) | FI3877395T3 (fr) |
| GE (1) | GEP20247626B (fr) |
| HR (1) | HRP20230230T1 (fr) |
| HU (2) | HU231240B1 (fr) |
| IL (1) | IL290973B2 (fr) |
| JO (1) | JOP20220041A1 (fr) |
| LT (1) | LT3877395T (fr) |
| MA (1) | MA54200B1 (fr) |
| MD (1) | MD3877395T2 (fr) |
| MX (1) | MX2022002603A (fr) |
| PE (1) | PE20221418A1 (fr) |
| PL (1) | PL3877395T3 (fr) |
| PT (1) | PT3877395T (fr) |
| RS (1) | RS63966B1 (fr) |
| SI (1) | SI3877395T1 (fr) |
| WO (1) | WO2021044302A1 (fr) |
| ZA (1) | ZA202203557B (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3101348B1 (fr) * | 2019-09-27 | 2024-01-19 | Ind Chimica Srl | PROCÉDÉ DE PRÉPARATION DE (15α,16α,17β)-OESTRA-1,3,5(10)-TRIÈNE-3,15,16,17-TÉTROL (OESTÉTROL) ET INTERMÉDIAIRES DUDIT PROCÉDÉ |
| GB2626482A (en) * | 2021-10-01 | 2024-07-24 | Ind Chimica Srl | Process for preparing (15alpha,16alpha,17eta)-estra-1,3,5-(10)-triene-3,15,16,17-tetrol(estetrol) monohydrate |
| WO2024160373A1 (fr) | 2023-02-02 | 2024-08-08 | Industriale Chimica S.R.L. | PROCÉDÉ DE PRÉPARATION DE MONOHYDRATE DE (15α,16α,17β)-ESTRA-1,3,5(10)-TRIÈNE-3,15,16,17-TÉTROL (ESTÉTROL) |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1260225A1 (fr) | 2001-05-18 | 2002-11-27 | Pantarhei Bioscience B.V. | Compositions pharmaceutiques pour le traitement hormonal substitutif |
| US8048869B2 (en) | 2001-05-18 | 2011-11-01 | Pantarhei Bioscience B.V. | Pharmaceutical composition for use in hormone replacement therapy |
| PT1390042E (pt) | 2001-05-23 | 2008-03-10 | Pantarhei Bioscience Bv | Sistema de administração de um medicamento que compreende estrogénio tetrahidroxilado destinado à contracepção hormonal |
| ATE449606T1 (de) | 2001-05-23 | 2009-12-15 | Pantarhei Bioscience Bv | Tetrahydroxylierte estrogen enthaltendes arzneistoffverabreichungssystem zur verwendung in hormonalen kontrazeption |
| WO2003041718A1 (fr) | 2001-11-15 | 2003-05-22 | Pantarhei Bioscience B.V. | Utilisation de composes oestrogenes combines a des composes progestogenes en therapie de substitution hormonale |
| US7943604B2 (en) | 2002-06-11 | 2011-05-17 | Pantarhei Bioscience B.V. | Method of treating human skin and a skin care composition for use in such a method |
| US7923440B2 (en) | 2002-06-11 | 2011-04-12 | Pantarhei Bioscience B.V. | Method of treating or preventing immune mediated disorders and pharmaceutical formulation for use therein |
| AU2003253506A1 (en) | 2002-07-12 | 2004-02-02 | Pantarhei Biosciences B.V. | Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy |
| SI1556058T1 (sl) | 2002-10-23 | 2008-02-29 | Pantarhei Bioscience Bv | Farmacevtski sestavki, ki obsegajo estetrolne derivate, za uporabo pri zdravljenju raka |
| US20060211669A1 (en) * | 2002-11-08 | 2006-09-21 | Verhaar Mark T | Synthesis of estetrol via estrone derived steroids |
| US20090221540A1 (en) | 2006-01-09 | 2009-09-03 | Pantarhei Bioscience B.V. | Method of Treating An Acute Vascular Disorder |
| CA2674325A1 (fr) | 2007-01-08 | 2008-07-17 | Pantarhei Bioscience B.V. | Methode de traitement ou prevention de la sterilite d'un mammifere feminin et trousse pharmaceutique associee |
| EP2383279A1 (fr) * | 2011-07-19 | 2011-11-02 | Pantarhei Bioscience B.V. | Procédé de préparation d'estetrol |
| PT2741824T (pt) | 2011-08-11 | 2017-07-06 | Estetra Sprl | Utilização de estetrol como contracetivo de emergência |
| US8987484B2 (en) * | 2011-10-07 | 2015-03-24 | Estetra S.P.R.L. | Process for the production of estetrol |
| EP2653163A1 (fr) | 2012-04-19 | 2013-10-23 | Université de Liège | Constituants estrogènes pour l'utilisation dans le traitement de troubles neurologiques |
| WO2013034780A2 (fr) | 2012-12-20 | 2013-03-14 | Crystal Pharma, S.A.U. | Procédé de préparation de l'estétrol et de composés analogues |
| JP6254289B2 (ja) | 2013-09-18 | 2017-12-27 | クリスタル ファルマ、エセ、ア、ウＣｒｙｓｔａｌ Ｐｈａｒｍａ，Ｓ．Ａ．Ｕ． | エステトロールの製造プロセス |
| NZ720906A (en) | 2013-12-12 | 2022-04-29 | Estetra Sprl | Orally disintegrating solid dosage unit containing an estetrol component |
| EP3310346B1 (fr) | 2015-06-18 | 2021-03-24 | Estetra SPRL | Comprimé orodispersible comprenant estetrol |
| EA035687B1 (ru) | 2015-06-18 | 2020-07-27 | Эстетра Спрл | Диспергируемая в полости рта единица дозирования, содержащая эстетрольный компонент |
| DK3310345T3 (da) | 2015-06-18 | 2021-05-25 | Estetra Sprl | Orodispersibel tablet indeholdende estetrol |
| CA3178291A1 (fr) | 2016-08-05 | 2018-04-12 | Estetra Srl | Methode de prise en charge de la dysmenorrhee et des douleurs menstruelles |
| KR20190076014A (ko) | 2016-10-28 | 2019-07-01 | 에스테트라 에스.피.알.엘. | 월경통 및 생리통의 관리방법 |
| BR112020002094A2 (pt) | 2017-08-01 | 2020-07-28 | Fund Sa | terapia adjuvante para o uso em tratamento de câncer de próstata |
| JP2021513507A (ja) | 2018-02-07 | 2021-05-27 | エステトラ ソシエテ プリーヴ ア レスポンサビリテ リミテ | 心臓血管系への影響を低減した避妊薬組成物 |
| FR3101348B1 (fr) * | 2019-09-27 | 2024-01-19 | Ind Chimica Srl | PROCÉDÉ DE PRÉPARATION DE (15α,16α,17β)-OESTRA-1,3,5(10)-TRIÈNE-3,15,16,17-TÉTROL (OESTÉTROL) ET INTERMÉDIAIRES DUDIT PROCÉDÉ |
-
2019
- 2019-09-03 HU HU1900315A patent/HU231240B1/hu unknown
-
2020
- 2020-09-02 HR HRP20230230TT patent/HRP20230230T1/hr unknown
- 2020-09-02 KR KR1020227010919A patent/KR20220071206A/ko unknown
- 2020-09-02 DK DK20768398.8T patent/DK3877395T3/da active
- 2020-09-02 RS RS20230112A patent/RS63966B1/sr unknown
- 2020-09-02 MX MX2022002603A patent/MX2022002603A/es unknown
- 2020-09-02 SI SI202030156T patent/SI3877395T1/sl unknown
- 2020-09-02 LT LTEPPCT/IB2020/058148T patent/LT3877395T/lt unknown
- 2020-09-02 CN CN202080061521.1A patent/CN114302889B/zh active Active
- 2020-09-02 CU CU2022000013A patent/CU24692B1/es unknown
- 2020-09-02 US US17/639,206 patent/US11633406B2/en active Active
- 2020-09-02 CA CA3147815A patent/CA3147815C/fr active Active
- 2020-09-02 JP JP2022511285A patent/JP7265087B2/ja active Active
- 2020-09-02 HU HUE20768398A patent/HUE061427T2/hu unknown
- 2020-09-02 GE GEAP202015920A patent/GEP20247626B/en unknown
- 2020-09-02 PT PT207683988T patent/PT3877395T/pt unknown
- 2020-09-02 JO JOP/2022/0041A patent/JOP20220041A1/ar unknown
- 2020-09-02 MD MDE20210894T patent/MD3877395T2/ro unknown
- 2020-09-02 MA MA54200A patent/MA54200B1/fr unknown
- 2020-09-02 IL IL290973A patent/IL290973B2/en unknown
- 2020-09-02 FI FIEP20768398.8T patent/FI3877395T3/fi active
- 2020-09-02 EP EP20768398.8A patent/EP3877395B1/fr active Active
- 2020-09-02 WO PCT/IB2020/058148 patent/WO2021044302A1/fr active Application Filing
- 2020-09-02 PL PL20768398.8T patent/PL3877395T3/pl unknown
- 2020-09-02 AU AU2020343497A patent/AU2020343497B2/en active Active
- 2020-09-02 PE PE2022000348A patent/PE20221418A1/es unknown
- 2020-09-02 ES ES20768398T patent/ES2855923T3/es active Active
-
2022
- 2022-02-28 CL CL2022000492A patent/CL2022000492A1/es unknown
- 2022-03-24 EC ECSENADI202222403A patent/ECSP22022403A/es unknown
- 2022-03-28 ZA ZA2022/03557A patent/ZA202203557B/en unknown
- 2022-03-29 CO CONC2022/0003769A patent/CO2022003769A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA54200A (fr) | Procédé industriel pour la préparation d'estétrol de pureté élevée | |
| MA49700A (fr) | Procédé amélioré pour la préparation de dérivés d'aminopyrimidine | |
| MA53370A (fr) | Procédé et intermédiaires pour la préparation de bilastine | |
| MA49628A (fr) | Processus pour la purification de l'acide hyaluronique | |
| MA55917A (fr) | Procédé de cristallisation de dérivés d'aripiprazole dans des formulations à libération prolongée pour le traitement de la schizophrénie | |
| WO2019224790A3 (fr) | Promédicaments de fulvestrant | |
| MA54522A (fr) | Composition pharmaceutique pour le traitement de l'hypertension artérielle pulmonaire | |
| MA54701A (fr) | Procédé de préparation de nutriments à partir d'insectes | |
| MA53554A (fr) | Procédé amélioré pour la préparation d'une protéine de lectine recombinante | |
| MA51870A (fr) | Procédé pour la préparation de composés coupleurs de médicaments | |
| FR1026700A (fr) | Procédé pour le filage de polymères supérieurs en fusion, produits obtenus par ce procédé, filières pour la mise en oeuvre de ce procédé, et procédé pour la fabrication de ces filières | |
| MA50124A (fr) | Procédé de préparation de tubulysines et d'intermédiaires de celles-ci | |
| MA50859A (fr) | Procédé pour la production d'une composition de lymphocytes t | |
| MA49703A (fr) | Nouveaux intermédiaires utiles pour la synthèse de dérivés d'aminopyrimidine, leur procédé de préparation et procédé de préparation de dérivés d'aminopyrimidine à l'aide de ceux-ci | |
| SG11202101575TA (en) | Process for the production of high purity isobutylene | |
| EP4211104C0 (fr) | Procédé de synthèse du 3,5-diiodo-4-hydroxy benzylalcool | |
| MA54502A (fr) | Procédé pour la préparation de granulés destinés à chauffer un four industriel | |
| MA52362A (fr) | Procédé de préparation de d'acide 2-(1-(tert-butoxylcarbonyl)-pipéridine-4-yl) benzoïque | |
| MA54817A (fr) | Procédé pour la préparation d'un polymère de lignosulfonate | |
| MA52183A (fr) | Procédé de préparation de 2,2-diméthylpipérazine | |
| ZA202207991B (en) | Novel processes for the preparation of rapid melt granules | |
| HUP2300098A1 (hu) | Eljárás upadacitinib elõállítására | |
| FR2693401B1 (fr) | Procédé pour la fabrication de tuyaux poreux et produits obtenus par ce procédé. | |
| IL287228A (en) | A process for producing modified 2-[2-(phenyl)ethylamino]alkanamide derivatives | |
| IL287230A (en) | A process for the production of modified 2-[2-(phenyl)ethylamino]alkanamide derivatives |